Article · 16 Sep 2026
Conference abstract
Novel polymer system for controlled delivery of chemotherapeutics to improve patient outcomes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Controlled drug delivery technologies have continued to evolve in recent years. The promise of controlled delivery is exemplified by sustained adequate levels of drug at the site of malignancy. Nowhere is the need for such technology more evident than the field of chemotherapy. Currently, chemotherapy is administered in a maximum tolerable dose format followed by a period (>3 weeks) of non-treatment for the patient. This administration schedule not only inflicts debilitating side effects on the patient but also allows the associated tumor time to regrow and develop resistance between treatments. The utilization of a controlled delivery system would allow for many improvements over the current paradigm, such as constant exposure of the malignancy to pharmaceutics, larger tolerable administrable dose, and lower side effects, amongst others. Poly-Med Inc. (PMI) has developed a system which allows for an increase in the level of tolerable drug at site as well as theoretical improved tumor response. PMI uses novel block copolymers to allow for superior control in terms of drug delivery. Such work holds great promise for improving patient outcomes in the clinic.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutica Analytica Acta.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Jason Olbrich”
